Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Introduction: Metastatic colorectal cancer (CRC) remains a dilemma for cancer researchers
with an increasing incidence in the younger patient population. Until the last decade, limited …

The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …

Importance Colorectal cancer (CRC) is the third most common cause of cancer mortality
worldwide with more than 1.85 million cases and 850 000 deaths annually. Of new …

Colorectal cancer (CRC) is a heterogeneous disease representing a therapeutic challenge,
which is further complicated by the common occurrence of several molecular alterations that …

Treatment strategies for metastatic colorectal cancer (mCRC) patients have undergone
dramatic changes in the past decade and despite improved patient outcomes, there still exist …

Although significant progress has been made in colorectal cancer (CRC) treatment within
the last decade with the approval of multiple new agents, the prognosis for patients with …

In the last two decades, great efforts have been made in the treatment of metastatic
colorectal cancer (mCRC) due to the approval of new target agents for cytotoxic drugs …

Colorectal cancer (CRC) is a significant cause of cancer-related morbidity and mortality all
over the world. Improvements of cytotoxic and biologic agents have prolonged the survival in …

Colorectal cancer is the second most common malignancy diagnosed in Canada. Despite
declining incidence and mortality rates in recent years, there is still a significant number of …